CVC and GBL launch €10.7B bid to take Recordati private: full analysis

CVC Capital Partners and Groupe Bruxelles Lambert have moved from interest to execution in their pursuit of Recordati, launching a voluntary cash tender offer worth roughly €10.7 billion to take the Italian drugmaker private. The offer is priced at €51.29 per share, ex-dividend, and is being made through newly formed Respighi BidCo with the stated goal of delisting Recordati from Euronext Milan. (gbl.com)

The move follows a non-binding indication of interest that CVC submitted to Recordati’s board on March 25, 2026. At that stage, the proposal depended on due diligence and the addition of partners. Those conditions have now been addressed: GBL has joined as a co-control investor, financing is described as fully committed, and a broader investor syndicate has been assembled. Recordati had already disclosed market rumors tied to CVC earlier this year, so the formal launch marks the point where speculation turned into a structured transaction. (gbl.com)

Several details make the bid unusually solid from the outset. Rossini, Recordati’s controlling shareholder, has irrevocably agreed to tender all 97.9 million shares it holds, equal to 46.82% of the company’s share capital. The consortium says the maximum cash outlay would be just over €10.726 billion if all shares are tendered. Completion is subject to the bidder reaching at least 66.67% of Recordati’s share capital, along with antitrust, foreign direct investment, and foreign subsidy-related clearances. Reuters also reported that the bidders may pursue a merger structure if acceptances fall short of the 90% threshold typically needed to complete a delisting directly. (gbl.com)

The offer price matches the preliminary terms floated in March. According to the bidder’s filing, the €51.29 per-share consideration, combined with the €0.71 dividend balance paid on May 20, 2026, implies a cum-dividend value of €52.00 and a 12.89% premium to Recordati’s undisturbed share price on March 25. Recordati, which reported €2.62 billion in 2025 net revenue, has been positioning itself as a long-term growth story spanning specialty and primary care as well as rare diseases, which helps explain why private capital sees room for more aggressive strategic moves outside public-market scrutiny. (gbl.com)

Industry reaction has been mixed. In the consortium’s own announcement, Rossini said private ownership would give Recordati more strategic flexibility and better support a phase that may require stepped-up R&D and M&A. Reuters separately cited Intermonte analyst Giorgio Tavolini saying the current price was not especially attractive for investors and might need to be raised to achieve a full delisting, though he also noted the market price suggested investors saw limited room for a sweetener. That split is telling: insiders are framing the deal as a long-term strategic reset, while some market observers see it as partly a shareholder reshuffle. (gbl.com)

Why it matters: For veterinary professionals, there’s no direct practice-level impact here today, because Recordati is not a frontline animal health supplier. Still, the deal matters as a readout on how healthcare capital is moving in Europe. Private equity and long-duration investors are signaling continued appetite for scaled pharma platforms with room for portfolio expansion, bolt-on acquisitions, and operational change. That can affect valuations, deal competition, and strategic priorities across adjacent health sectors, including animal health, diagnostics, specialty therapeutics, and distribution. In other words, even when a transaction sits outside veterinary medicine, it can still shape the market conditions veterinary companies operate in. (marketscreener.com)

There’s also a practical takeaway for industry watchers: the rationale behind this bid is less about turnaround and more about freedom to invest. The consortium’s messaging emphasizes strategic flexibility, stable capital, and the ability to pursue a more demanding growth phase. That’s a familiar argument in healthcare, where public companies can face pressure for near-term earnings even as they weigh longer R&D timelines, specialty launches, or acquisitions. Veterinary executives and investors will recognize that same tension in animal health, especially as companies balance innovation spending with margin expectations. (gbl.com)

What to watch: The next steps are the publication of the formal offer document, regulatory review, the opening of the acceptance period, and whether the bidder can move beyond the 66.67% minimum toward a full delisting. If the offer closes on current terms, Recordati could become another example of a sizable healthcare platform shifting into private hands to pursue a more acquisition-heavy, longer-horizon strategy. (gbl.com)